Optometry Times

Q: What is the address?

24950 Country Club Boulevard, Ste 200

Practical chairside advice Posting Policy:
Thank you for liking the official Optometry Times page. We're glad you're here.

We are committed to creating a community that encourages self-expression and mirrors the values of Optometry Times including respect for the rights, dignity, and property of others. We ask all fans to do their part to help us achieve the goal. In doing that, we ask you not to post content that:
-is threatening, abusive, obscene, indecent, or objectionable.
-is deceptive, false, or misleading
-viol

ates the intellectual property rights of other people
-is illegal
-references a third party website or is self-promoting spam
-is inappropriate, offensive, or hateful
We reserve the right to remove any content or block users that violate our community guidelines, or that we determine are otherwise offensive to our community. All content must also comply with Facebook's policies as well. We would be sorry to see you go, but if you change your mind and no longer want to like our page, please feel free to "unlike" our page.

02/09/2025

Six more weeks of winter? How about five more top stories of the week from Optometry Times instead?: https://www.optometrytimes.com/view/what-happened-in-optometry-this-week-february-3---february-7

02/08/2025

Lumenis, creator of OptiLIGHT, has revealed a new addition to their portfolio: OptiLIFT, a noninvasive device that leverages Dynamic Muscle Stimulation (DMSt™) technology to tone facial muscles and improve lower lid laxity and thus impaired blinking. The device is now available in the United States and will follow in additional markets.

OptiLIFT uses proprietary DMSt, which, as the name implies, stimulates muscles in the periorbital area with electrical impulses to tighten and tone. Over time, the muscle strengthens, improving function of the lower eyelid. The reduction in lid laxity was investigated in a recent clinical study, led by James Chelnis, MD, FACS, and the results showed 75% reduction in lid laxity, 70% improvement in blinking quality, and a 286% increase in tear breakup time following use of OptiLIFT.

Read more: https://www.optometrytimes.com/view/lumenis-unveils-optilift-for-lower-lid-laxity-and-impaired-blinking

02/07/2025

👀 Struggling to keep up with the latest in optometry? Tired of sifting through endless articles? There’s a better way! Optometry Times delivers the insights you need—fast, easy, and straight to the point. But wait, there’s more… watch our new infomercial now!

www.optometrytimes.com

02/07/2025

"As an eye care provider with a patient-first approach, I prefer shorter wear cycles for contact lenses, which may deliver improvements in comfort and overall patient compliance. What’s more, the residual business benefits of the resulting increased patient compliance and comfort correlate to better patient outcomes, satisfaction, and loyalty, and reduce the risk factors that may contribute to lens dropout. Though a shorter lens replacement schedule, such as for a daily disposable, has many advantages, some patients still require reusable lenses for various reasons. With increased innovations coming to market, new reusable lenses with shorter replacement intervals, such as a 1-week schedule, have the potential to satisfy the unmet needs of patients and providers alike," writes Janelle Davison, OD.

Read more: https://www.optometrytimes.com/view/the-dual-advantage-of-a-shorter-lens-replacement-schedule

02/06/2025

The US Food and Drug Administration (FDA) has approved ranibizumab injection) 100 mg/mL (Susvimo; Genentech) for the treatment of diabetic macular edema (DME). The company noted that Susvimo is the “first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections.”

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time. Susvimo was previously called the Port Delivery System with ranibizumab in the US.

Read more: https://www.optometrytimes.com/view/fda-approves-ranibizumab-for-the-treatment-of-diabetic-macular-edema-via-continuous-delivery-implant

02/05/2025

A new study from South Korea suggests that the presence of migraines may be a possible risk factor for open angle glaucoma (OAG). Led by Hyung Jun Kim, MD, from the Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine in Seoul, the study examined a 12-year nationwide cohort and found that patients who experience migraines showed a significantly increased risk of developing OAG. However, significant differences were not recorded between the study groups when assessing the presence of aura (migraine with aura: HR: 1.235; 95% CI: 1.137–1.342, P < 0.001; migraine without aura: HR: 1.248; 95% CI: 1.143–1.363, P < 0.001).

Read more:
https://www.optometrytimes.com/view/south-korean-study-suggests-migraines-may-be-a-risk-factor-for-oag

02/04/2025

Measuring visual acuity (VA) is one of the first skills that eye care professionals learn during their training, as it is among the most important measures of an individual’s ocular and visual health. Health care practitioners can more consistently assess a patient’s condition or visual status when they use standardized VA measurements, such as Snellen 20/20 or logMAR units. These data are essential for determining whether there are any underlying eye issues.

Most frequently, VA tests aid in identifying any refractive errors that require the use of spectacles or contact lenses to improve VA. The degree of myopia, hyperopia, astigmatism, or presbyopia could be assessed with the magnitude of visual acuity deficit. Corrective lenses should ideally completely restore the patient’s VA. If glasses or contact lenses fail to fully correct a patient’s eyesight, it is necessary to identify and adequately justify an ocular health deficit as the cause of the impaired vision.

Read more:
https://www.optometrytimes.com/view/back-to-the-basics-understanding-methods-for-measuring-visual-acuity

02/03/2025

EssilorLuxottica has received medical device approval from the FDA for its over-the-counter Nuance Audio Glasses, which integrates open-ear hearing aid into a pair of smart glasses. Concurrently, the device received CE marking under the Medical Devices Regulation in the EU as well as an ISO Quality Management System certification for Hearing Aids. The sweep of approvals will allow the glasses to launch in the US and Europe simultaneously.

Read more:
http://optometrytimes.com/view/nuance-audio-hearing-aid-glasses-receive-fda-approval-as-a-medical-device

02/02/2025

The days are only getting longer from here! Enjoy the extra sunshine and catch up on all things optometric:
https://ow.ly/YYY850URvov

02/01/2025

A recent study from China found that the central corneal temperature of patients who have either insufficient recovery time from COVID-19 infection or who exhibit severe infection symptoms could decrease faster when their eyes are open, compared to those with moderate and low post-COVID-19 fever and no fever. Led by Chunbo Wu of the School of Optical Electrical and Computer Engineering, University of Shanghai for Science and Technology in Shanghai, study authors stated that this faster decrease indicates a faster evaporation of the tear film could be due to dry eye disease (DED), although a correlation between DED and COVID-19 infection has not been established.

Read more: https://www.optometrytimes.com/view/recent-study-finds-high-post-covid-19-infection-fever-could-impact-central-corneal-temperature

01/31/2025

We've just taken the CRU wine personality quiz, and we think you should, too! Find out which wine fits your personality and learn about the 2025 CRU Eye Symposium! We're a rosé; what are you?

Take the quiz here: https://ow.ly/BX3y50URsUy

01/31/2025

Glaucoma is a leading cause of irreversible blindness worldwide. The pathogenesis of glaucoma is not entirely understood; however, major risk factors are well established and include advancing age, genetic predisposition, and increased intraocular pressure (IOP). The only known modifiable risk factor is IOP. Evidence-based treatments to lower IOP include topical ophthalmic medications, laser procedures, sustained release implants, and/or surgical interventions. The most common approach for managing glaucoma, especially for the primary care optometrist, is IOP-lowering medication. Often patients with glaucoma are on multiple topical therapeutic agents to achieve optimal IOP measurements. While effective at lowering IOP, topical medications have historically contained preservatives. Preservatives are detergents used to prolong the shelf life of medications and maintain sterility; however, their presence can also have some adverse effects on the eye and cause challenges for the ocular surface.

The world’s population is aging, resulting in an increase in the geriatric demographic, leading to a rise in certain diseases, including glaucoma. It is estimated that approximately 3 million Americans are currently being treated for glaucoma and this number is expected to double by 2050. The Glaucoma Research Foundation reports a dramatic increase in glaucoma diagnosis in patients over 60 years; coupled with an estimated life expectancy in the US of 77.5 years, this means that most patients with glaucoma are relying on topical antiglaucoma medications for years, if not decades. The risk of developing ocular surface complications increases with the duration of topical therapy use and the number of preserved topical therapies a patient uses. As optometrists, we should be mindful of these ocular surface issues and prescribe with patient compliance, comfort, and quality of life in mind.

Read more:
https://www.optometrytimes.com/view/opening-our-eyes-to-the-impact-of-preservatives

01/30/2025

Currently, one-third of children and adolescents worldwide have myopia, with the prevalence expected to dramatically increase by the year 2050.1 Although our profession has made significant strides in progressing myopia management toward standard of care, optometrists still face challenges implementing myopia management into everyday clinical practice. Parents are often skeptical about what they may perceive as a novel approach to myopia, may have cost concerns, or even be fearful of potential adverse effects that contact lenses or eye drops may have on their child. To make the most impact on our concerted fight against myopia, we need a plethora of options to accommodate each type of patient, refractive error, and budget. This article will highlight the future of myopia management and what options are on the horizon.

Read more:
https://www.optometrytimes.com/view/what-s-on-the-horizon-for-myopia-management-

01/29/2025

A recent study discovered that medical professionals should utilize caution when performing comprehensive sideline sports-related concussion (SRC) assessments for return to play decisions, as exercise can affect women’s visual performance. The study, published in Journal of Optometry, found that of the visual assessments conducted, accommodation facility (d = 1.604), saccadic eye movement (d = 0.952), speed of recognition (d = 1.475), peripheral awareness (d = 1.961), and hand-eye coordination (d = 1.139) were most affected (P < 0.05) by a single bout of maximal aerobic exercise.

Read more: https://www.optometrytimes.com/view/study-finds-exercise-induced-changes-in-visual-performance-calls-for-reevaluation-of-src-efficacy

01/28/2025

Earlier this month, EssilorLuxottica acquired Pulse Audition, a French startup that delivers artificial intelligence (AI) based noise reduction and voice enhancement through the utilization of algorithms, according to a news release. The technology, which allows people with hearing impairment to better understand speech, particularly in noisy environments, can be embed into eyeglasses, as seen in Pulse’s Pulse Frames.

Read more: https://ow.ly/Axh250UMByC

01/25/2025

Edinburgh Innovations, the University of Edinburgh’s commercialization service, announced a research program which will use artificial intelligence (AI)-based software and anonymized eye scans from patients throughout Scotland. The NeurEYE research team, led by the University of Edinburgh and in conjunction with Glasgow Caledonian University, will use millions of eye scans from Scottish optometrists to create the data set. Permission to use the data comes from the Public Benefit and Privacy Panel for Health and Social Care, a part of NHS Scotland. Once data is collected and anonymized, researchers will apply AI and machine learning tools to analyze the images for dementia risk and other bioindicators of brain health.

Read more: https://www.optometrytimes.com/view/neureye-research-team-leads-ai-supported-dementia-detection-program-with-optometrists-in-scotland

01/24/2025

CRU is returning to Napa Valley, California, this March! Get ready for education from the most influential minds in eye care. Take our short quiz and discover your wine 🍷 persona to get excited for Napa Valley!

Click here to take the quiz: https://ow.ly/Wj5q50UMbTs

Click here to learn more about the 2025 CRU Eye Symposium: https://ow.ly/ng0n50UMbTt

01/24/2025

IU scientists have received funding support for a new program from the National Institutes of Health to support the emerging field of oculomics, which uses the eye as an avenue to investigate diseases that affect the whole body. The 3 year, $4.8 million award comes from the NIH Venture Program Oculomics Initiatives and will support the development of next generation ophthalmoscopes, which can detect early warning signs of conditions such as diabetes, heart and kidney disease, sickle cell anemia, and Alzheimer disease by scanning the eye.

Read more:
https://www.optometrytimes.com/view/indiana-university-receives-funding-for-advancing-oculomics

Address

24950 Country Club Boulevard, Ste 200
North Olmsted, OH
44070

Telephone

+14402438100

Website

https://www.optometrytimes.com/

Alerts

Be the first to know and let us send you an email when Optometry Times posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Optometry Times:

Videos

This Thanksgiving, we’re thankful for you—the optometry community driving innovation and improving lives. Wishing you and your loved ones a joyful holiday! 🍁

🚨 November Issue Alert! 🚨 The latest edition of Optometry Times is out now. Stay ahead with the latest research and insights in the field of optometry. Access the November 2024 issue here: https://ow.ly/MlwC50UgXwu #NewIssue #Optometry

🚨October Issue Alert! 🚨 The latest edition of Optometry Times is out now. Stay ahead with the latest research and insights in the field of optometry. Access the October 2024 issue here: https://bit.ly/ODIssue

🚨 September Issue Alert! 🚨 The latest edition of Optometry Times is out now. Stay ahead with the latest research and insights in the field of optometry. Access the September 2024 issue here: https://bit.ly/ODIssue

This post is sponsored by the American Academy of Optometry. New this year at Academy 2024 Indianapolis is the Academy’s Clinical Procedures Skills Transfer Program, divided into two parts: Laser Skills and Minor Surgical Skills. Register for one or both parts this November! Watch a sneak peek of what to expect from several program speakers: https://ow.ly/pIHy50SYQHu #Academy24 #fellows #optometry #loveindy #ad

Optometry Times August Issue Alert

🚨 August Issue Alert! 🚨 The latest edition of Optometry Times is out now. Stay ahead with the latest research and insights in the field of optometry. Access the August 2024 issue here: https://bit.ly/ODIssue

We are excited to invite you to EyeCon 2024 in Fort Lauderdale, FL! This premier event is tailored for ophthalmologists and optometrists eager to stay ahead in eye care. Join us for insightful presentations on the latest advancements, invaluable networking opportunities, and explore cutting-edge technologies and innovations in our exhibit hall. 🚨 Early Bird Pricing Ends This Thursday 🚨 Don't miss out on the savings—register now and secure your spot. We look forward to welcoming you to Fort Lauderdale and advancing the future of eye care together! 👉 Register today: https://ow.ly/grcC50SyMY5

🎤Hear from Dr. Kelly Nichols on why optometrists should join her at EyeCon 2024! With her cutting-edge insights and extensive expertise, she'll be sharing invaluable knowledge that you won't want to miss. Join us in Fort Lauderdale for a transformative experience in optometry. Early bird pricing ends August 1st—register now! https://ow.ly/Q7Fi50SHJyM

We are excited to invite you to EyeCon 2024 in Fort Lauderdale, FL! This premier event is tailored for ophthalmologists and optometrists eager to stay ahead in eye care. Join us for insightful presentations on the latest advancements, invaluable networking opportunities, and explore cutting-edge technologies and innovations in our exhibit hall. 🚨 Early Bird Pricing Ends August 1, 2024 🚨 Don't miss out on the savings—register now and secure your spot. We look forward to welcoming you to Fort Lauderdale and advancing the future of eye care together! 👉 Register today:https://ow.ly/7hOP50SrMzU

🚨 June Issue Alert! 🚨 The latest edition of Optometry Times is out now. Stay ahead with the latest research and insights in the field of optometry. Access the June 2024 issue here: https://bit.ly/3XA1CF9

Exclusive interview with EyeCon's event chair, Paul Chous, discussing what makes EyeCon a standout event in the optometry world! Don't miss out on our early bird prices – secure your spot before the prices go up! https://ow.ly/2zS950S4oqQ

Optometry Times

02/09/2025

02/08/2025

02/07/2025

02/07/2025

02/06/2025

02/05/2025

02/04/2025

02/03/2025

02/02/2025

02/01/2025

01/31/2025

01/31/2025

01/30/2025

01/29/2025

01/28/2025

01/25/2025

01/24/2025

01/24/2025

Address

Telephone

Website

Alerts

Contact The Business

Videos

Optometry Times August Issue Alert

Shortcuts

Share

Category